• All
  • Financials
  • Insiders
Webull provides the latest Vera Therapeutics, Inc. (VERA) stock and general news. This information may help you make smarter investment decisions.
About VERA
Vera Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a biologic inhibitor of B cells and plasma cells. Atacicept is self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Atacicept is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis, kidney transplant, serious disease, and early death. It is also developing MAU868, a monoclonal antibody that neutralizes infection with BK Virus.